GVP: good pharmacovigilance practices

Good pharmacovigilance practices (GVP) are the EMA guidelines that set out how holders and authorities carry out pharmacovigilance in the EU.

Also known as: GVP guidelines, GVP modules, guideline on good pharmacovigilance practices

3 min readUpdated

Reviewed by Gosia Luksza, CEO at Regunaut

At a glance

Legal basis
Article 108a of Directive 2001/83/EC
Issued by
EMA, with the national competent authorities
Structure
Modules I to X, XV and XVI, chapters on specific products and populations, and annexes
Applies to
Marketing authorisation holders, EMA and national authorities, for centrally and nationally authorised medicines

How it works

Good pharmacovigilance practices are a set of guidelines drawn up by EMA in cooperation with the competent authorities of the Member States and other interested parties, as Article 108a of Directive 2001/83/EC requires. They were a key deliverable of the 2010 pharmacovigilance legislation, and the first modules took effect in July 2012. GVP applies to marketing authorisation holders, to EMA and to the national authorities, and it covers centrally and nationally authorised medicines alike.

The guidance is organised in modules, each covering one major process. Module I deals with pharmacovigilance systems and their quality systems, II with the pharmacovigilance system master file, III with inspections, IV with audits, V with risk management systems, VI with the collection, management and submission of reports of suspected adverse reactions, VII with the periodic safety update report, VIII with post-authorisation safety studies, IX with signal management, X with additional monitoring, XV with safety communication and XVI with risk minimisation measures. Numbers XI to XIV stay void, because their planned topics were addressed in other EMA guidance. Several modules have addenda, for example on duplicate management of case reports and on methods for evaluating the effectiveness of risk minimisation. Alongside the modules sit chapters on product- or population-specific considerations, covering vaccines, biological medicines, pregnant and breastfeeding women and the paediatric population, and annexes with definitions, templates and the related ICH guidelines.

GVP is guidance, not legislation. The binding rules are in Directive 2001/83/EC, Regulation (EC) No 726/2004 and Commission Implementing Regulation (EU) No 520/2012, and the modules explain how to meet them. The wording marks the difference: 'shall' introduces a requirement taken from the legislation, and 'should' a recommendation on how to implement it. In practice the distinction matters less than it seems, because inspectors assess a holder's system against GVP, and a holder that departs from a recommendation is expected to show that its alternative achieves the same result. Each module is revised separately, usually after public consultation, and carries its own revision number and effective date.

What goes wrong

Standard operating procedures that cite a superseded revision of a module; affiliates and partners outside the EU that follow local rules only, although the holder's EU obligations cover data from every country; reading 'should' as optional and keeping no documented justification for doing something else; applying one module in isolation, for example planning a safety study under Module VIII without updating the risk management plan under Module V; and missing a revision because nobody is assigned to watch for it. Pharmacovigilance inspections assess the system against the legislation and GVP together, so gaps of this kind turn into findings.

What teams do with it in Regunaut

Jobs in the platform that turn on GVP, each part of a wider workflow.

GVP: common questions

Is GVP legally binding?

Not in itself. GVP is guidance issued by EMA under Article 108a of Directive 2001/83/EC. The binding obligations are in the Directive, Regulation (EC) No 726/2004 and Implementing Regulation (EU) No 520/2012. Where a module says 'shall', it is restating one of those legal requirements; where it says 'should', it recommends how to comply. Inspectors use GVP as the benchmark, so departures need a documented justification.

How many GVP modules are there?

Twelve are in use: Modules I to X, XV and XVI. The numbers XI, XII, XIII and XIV were reserved for topics that EMA later addressed in other guidance, so they stay void. Several modules have addenda, and there are separate chapters on product- or population-specific considerations for vaccines, biological medicines, pregnancy and breastfeeding, and children.

Does GVP apply to generics and nationally authorised products?

Yes. GVP applies to every marketing authorisation holder in the EU, whatever the legal basis of the application and whether the product is authorised centrally, through the decentralised or mutual recognition procedure, or nationally. Some obligations are lighter for certain products, such as the exemption of generics from routine PSURs, but the pharmacovigilance system, case reporting and signal management requirements apply to all.

Sources

  1. European Medicines Agency: Good pharmacovigilance practices (GVP)
  2. EUR-Lex: Directive 2001/83/EC on the Community code relating to medicinal products for human use (Article 108a)
  3. EUR-Lex: Commission Implementing Regulation (EU) No 520/2012 on the performance of pharmacovigilance activities

Put your GVP question to Workbench

Workbench answers regulatory questions from EUR-Lex, EMA, national agencies and your own documents, with every claim linked to its source. Start free with welcome credits.